Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | PLD2 | O14939 | 3/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476321 | 0.87 | CHRM1 (0.71) | OPRM1CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL5478755 | 0.83 | CHRM1 (0.79) | OPRM1CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL5478167 | 0.79 | CHRM1 (0.63) | OPRM1CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL5482356 | 0.77 | CHRM1 (0.67) | OPRM1CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL5476534 | 0.75 | CHRM1 (0.71) | OPRM1CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL28604447 | 0.74 | OPRM1 (0.60) | OPRM1CHRM1DRD2PLD2PLD1 | |
| SCHEMBL25291004 | 0.73 | OPRM1 (0.61) | OPRM1CHRM1DRD2PLD2PLD1 | |
| SCHEMBL6577930 | 0.73 | CHRM1 (0.59) | OPRM1CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL22122308 | 0.71 | OPRM1 (0.59) | OPRM1CHRM1DRD2CHRM2CHRM4 | |
| SCHEMBL5470988 | 0.71 | CHRM1 (0.82) | OPRM1CHRM1DRD2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279490-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO, INC. (US) | 2007-10-09 | — | — | US | claimed |
| EP-1515722-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050176765-A1 | Ophthalmic compositions for treating ocular hypertension | MSD K.K. (JP) | 2005-08-11 | — | — | US | claimed |
| EP-1515722-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | claimed |
| WO-2003105781-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | claimed |
| US-7279490-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279490-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279490-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1515722-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050176765-A1 | Ophthalmic compositions for treating ocular hypertension | MSD K.K. (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1515722-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003105781-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176765-A1 | Ophthalmic compositions for treating ocular hypertension | CHRM1, CHRM2, CHRM5 | OPRM1 69/4885CHRM1 1/4885DRD2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.